


GFH603: A molecular glue–like allosteric activator of the KEAP1-CUL3 E3 ligase complex for targeting NRF2-activated tumors



Preclinical evaluation of GFH276 monotherapy and combination therapy for RAS-mutant tumors

Introduction

Conclusions

Introduction

Results

GFS784 is a novel EGFR-targeted ADC equipped with a panRAS(ON) inhibitor payload.